FDA Seeks More Safety Data on Foundayo GLP-1

The FDA requests additional safety data from the manufacturer of Foundayo GLP-1. This weight-loss drug faces scrutiny as regulators push for more evidence on potential risks. Patients and doctors await the results amid rising demand for GLP-1 treatments. The move highlights ongoing efforts to ensure drug safety. Read more about this...